Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

a maximum of 20 weeks passed without reaching this goal (unsuccessful tapering of steroids)[1]. In Part II of the study, patients were randomized to either continue receiving ACZ885, or to receive placebo every 4 weeks, until a pre-specified number (37) of flare-events ("flares") had occurred[1].

The primary endpoints were to: a) assess if ACZ885 allows tapering of steroids in at least 25% of SJIA patients (Part I); and b) demonstrate that time to next flare is extended with ACZ885 vs. placebo (Part II)[1].

In Part I of the study (representing 58 patient years), 138 of 177 patients (78%) reported an adverse event (AE), with the most common being nasopharyngitis, headache and cough. Serious adverse events (SAEs) were reported in 15 patients, with the most common being infections, MAS (four cases) or flare-associated events[1]. Five SAEs led to discontinuation, and one patient died of MAS[1]. During Part II, AEs (the most common being arthralgia, cough, nasopharyngitis and pyrexia) were reported by 40 of 50 (80%) ACZ885-treated patients (vs. 35 of 50 [70%] placebo patients previously treated with ACZ885)[1]; and six patients in each arm experienced one or more SAE, which mainly included infections, MAS and flare-associated events[1]. Six patients, all in the placebo arm, discontinued the study due to AEs or SAEs during Part II[1]. One patient died from MAS after study discontinuation in the placebo group.

MAS is a potentially fatal condition known to be associated with SJIA and is characterized by liver abnormalities, bleeding disorders, central nervous system dysfunction and multiple organ failure[4]. Approximately 10% of SJIA patients are diagnosed with MAS, some of whom suffer repeated episodes[4].

About ACZ885ACZ885 is a fully human monoclonal antibody that inhibits IL-1 beta, which is an important part of the body's immune system defenses. Excessive production of IL-1 beta plays a major role in certain inflammatory d
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... The Movement for Indefinite Life Extension (MILE) ... technologies and awareness. The event is taking place from ... 21st 2015, in a live Google Hangout broadcast from ... of MILE, says, “Our lives are in our hands, ... Indefinite Life Extension is raising awareness about bio-sciences and ...
(Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
(Date:2/26/2015)... Feb. 26, 2015 BioEnterprise today announced that ... attracted more than $2 billion in growth funding during ... national investors, strategic sources, state – including the Ohio ... the $2 billion has been raised in the past ... the heels of the BioEnterprise Midwest Healthcare Growth ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2
... Jan. 19, 2011 LifeVantage Corporation (OTC Bulletin ... to oxidative stress, announced preliminary unaudited net revenue for its ... of approximately $7.4 million for the three month period ended ... million or 15% over net revenue of $6.4 million for ...
... University have placed nanocrystals of rock salt into lead ... heat-generating items such as vehicle exhaust systems, industrial processes ... have seen in the past. The material exhibits ... to enable 14 percent of heat waste to electricity, ...
... Masimo (Nasdaq: MASI ... clinical accuracy of its noninvasive and continuous hemoglobin (SpHb®) monitoring ... for Technology in Anesthesia (STA) Annual Meeting . ... evaluated the accuracy of Masimo SpHb— a noninvasive measurement ...
Cached Biology Technology:LifeVantage Announces Preliminary Unaudited Second Quarter 2011 Results 2LifeVantage Announces Preliminary Unaudited Second Quarter 2011 Results 3Breakthrough in converting heat waste to electricity 2New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 2New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 3New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 4New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 5New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 6
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... the United States are 32 times more likely to ... antibiotic, gentamicin, than others outside the poultry industry, according ... Johns Hopkins Bloomberg School of Public Health. While drug-resistant ... industrial broiler chicken environment, this is the first U.S. ...
... possum and a giant rat were recorded by scientists as ... and virtually unknown Lost World in the pristine wilderness of ... Indonesia Institute of Science (LIPI) scientists were accompanied by the ... its wildlife on an expedition to the Fojas in June ...
... the Neural Basis of Cognition (CNBC), a joint project ... have for the first time described a mechanism called ... the fly allowing stimuli to be more keenly sensed. ... the January 2008 issue of Nature Neuroscience, and available ...
Cached Biology News:Poultry workers at increased risk of carrying antibiotic-resistant E. coli 2Indonesia's 'Lost World' reveals more surprises 2Neuronal circuits able to rewire on the fly to sharpen senses 2
Request Info...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
... Anti-PLCδ-1, clone d1-174 GenBank Accession ... and X-press N-terminal tagged fusion protein corresponding ... Formulation: 0.1M Tris-glycine, pH 7.4, 0.15M NaCl, ... glycerol to 30% Quality Assurance: routinely evaluated ...
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Biology Products: